Epidemiology of primary CNS lymphoma
- PMID: 10563423
- DOI: 10.1023/a:1006290032052
Epidemiology of primary CNS lymphoma
Abstract
In the beginning of the nineties the National Cancer Institute Surveillance, Epidemiology, and End Results Program calculated the incidence of primary central nervous system non-Hodgkin's lymphoma (PCNSL) as 1:100000. The incidence of PCNSL has been increasing since the seventies in immunocompetent patients. The main increase, however, is taking place since the mid-eighties and is due to the increase of immunodeficiency and immunosuppression. The risk is 2-6% in AIDS patients according to clinical data and will probably further increase with the length of survival in these patients. Transplant patients carry a risk of 1-5% to develop a PCNSL. The risk is 1-2% for renal, and 2-7% for cardiac, lung or liver transplant recipients. Patients with congenital immune deficiency have a risk of 4%. PCNSL may also present as a secondary malignancy.
Similar articles
-
Incidence and outcomes of primary central nervous system lymphoma in solid organ transplant recipients.Am J Transplant. 2018 Feb;18(2):453-461. doi: 10.1111/ajt.14465. Epub 2017 Sep 2. Am J Transplant. 2018. PMID: 28805292 Free PMC article.
-
Pathology with clinical correlations of primary central nervous system non-Hodgkin's lymphoma. The Massachusetts General Hospital experience 1958-1989.Cancer. 1994 Aug 15;74(4):1383-97. doi: 10.1002/1097-0142(19940815)74:4<1383::aid-cncr2820740432>3.0.co;2-1. Cancer. 1994. PMID: 8055462
-
AIDS malignancies in the era of highly active antiretroviral therapy.Oncology (Williston Park). 2002 Apr;16(4):441-51, 456, 459. Oncology (Williston Park). 2002. PMID: 12017534 Review.
-
The changing incidence of primary central nervous system lymphoma is driven primarily by the changing incidence in young and middle-aged men and differs from time trends in systemic diffuse large B-cell non-Hodgkin's lymphoma.Am J Hematol. 2013 Dec;88(12):997-1000. doi: 10.1002/ajh.23551. Epub 2013 Sep 12. Am J Hematol. 2013. PMID: 23873804 Free PMC article.
-
Histopathology, pathogenesis and molecular genetics in primary central nervous system lymphomas.Histol Histopathol. 2004 Jan;19(1):211-9. doi: 10.14670/HH-19.211. Histol Histopathol. 2004. PMID: 14702189 Review.
Cited by
-
Dual PI3K/HDAC Inhibitor BEBT-908 Exhibits Potent Efficacy as Monotherapy for Primary Central Nervous System Lymphoma.Target Oncol. 2023 Nov;18(6):941-952. doi: 10.1007/s11523-023-01006-z. Epub 2023 Oct 19. Target Oncol. 2023. PMID: 37855991
-
From the ER to the OR: Initial Evaluation of Primary Central Nervous System Lymphoma.Neurologist. 2023 May 1;28(3):135-142. doi: 10.1097/NRL.0000000000000475. Neurologist. 2023. PMID: 37027168 Review.
-
Primary Brainstem Lymphoma: A Population-Based Study.Front Surg. 2022 Jul 6;9:829048. doi: 10.3389/fsurg.2022.829048. eCollection 2022. Front Surg. 2022. PMID: 35874127 Free PMC article.
-
Comparative Molecular Analysis of Primary Central Nervous System Lymphomas and Matched Vitreoretinal Lymphomas by Vitreous Liquid Biopsy.Int J Mol Sci. 2021 Sep 16;22(18):9992. doi: 10.3390/ijms22189992. Int J Mol Sci. 2021. PMID: 34576156 Free PMC article.
-
Vitreoretinal Lymphoma.Cancers (Basel). 2021 Aug 4;13(16):3921. doi: 10.3390/cancers13163921. Cancers (Basel). 2021. PMID: 34439078 Free PMC article. Review.